Becaplermin (be kap' ler min; Regranex - Ortho-McNeil), a 0.01% topical gel formulation of recombinant human platelet-derived growth factor (rhPDGF), was recently approved by the FDA for adjunctive treatment of diabetic ulcers of the lower extremities that extend subcutaneously or beyond and have an adequate blood supply. Endogenous platelet-derived growth factor increases proliferation of cells that repair wounds and form granulation tissue....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
Information about the article:
Title: Platelet-Derived Growth Factor for Diabetic Ulcers
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1031
Article Code: 1031b
Date: July 17, 1998
Volume: 40
Pages: 73-74